208 related articles for article (PubMed ID: 31092773)
1. Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.
Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M
Intern Med; 2019; 58(10):1479-1484. PubMed ID: 31092773
[TBL] [Abstract][Full Text] [Related]
2. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
Sari M; Saip P
J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
[TBL] [Abstract][Full Text] [Related]
3. Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.
Nakahara Y; Fukui T; Shirasawa M; Harada S; Kusuhara S; Takakura A; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N; Inukai M; Sekiguchi T; Naoki K
Intern Med; 2018 Nov; 57(21):3149-3152. PubMed ID: 29877291
[TBL] [Abstract][Full Text] [Related]
4. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I
Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594
[TBL] [Abstract][Full Text] [Related]
5. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
6. Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report.
Pluvy J; Brosseau S; Stelianides S; Danel C; Nguenang M; Khalil A; Crestani B; Zalcman G; Gounant V
BMC Pulm Med; 2019 Jan; 19(1):12. PubMed ID: 30634951
[TBL] [Abstract][Full Text] [Related]
7. Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.
Sasatani Y; Okauchi S; Ohara G; Kagohashi K; Satoh H
Clin Respir J; 2019 Oct; 13(10):657-658. PubMed ID: 31343829
[No Abstract] [Full Text] [Related]
8. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
9.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
10. Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases.
Warth A; Körner S; Penzel R; Muley T; Dienemann H; Schirmacher P; von Knebel-Doeberitz M; Weichert W; Kloor M
Virchows Arch; 2016 Mar; 468(3):313-9. PubMed ID: 26637197
[TBL] [Abstract][Full Text] [Related]
11. A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.
Watanabe H; Ohashi K; Nishii K; Seike K; Makimoto G; Hotta K; Maeda Y; Kiura K
Intern Med; 2019 Oct; 58(20):3033-3037. PubMed ID: 31292383
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
Check JH; Check D; Poretta T
Anticancer Res; 2019 Apr; 39(4):1923-1926. PubMed ID: 30952734
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and Treatment of MSI-H Cancer in Gynecological Cancer].
Yamamoto N; Tashiro H; Katabuchi H
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1577-1581. PubMed ID: 30449841
[TBL] [Abstract][Full Text] [Related]
14. Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab.
Senoo S; Ninomiya T; Makimoto G; Nishii K; Kano H; Watanabe H; Hata Y; Kubo T; Tanaka T; Hotta K; Maeda Y; Kiura K
Intern Med; 2019 Apr; 58(7):985-989. PubMed ID: 30568113
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab for the treatment of colorectal cancer.
Smith KM; Desai J
Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
Takamochi K; Takahashi F; Suehara Y; Sato E; Kohsaka S; Hayashi T; Kitano S; Uneno T; Kojima S; Takeuchi K; Mano H; Suzuki K
Lung Cancer; 2017 Aug; 110():26-31. PubMed ID: 28676214
[TBL] [Abstract][Full Text] [Related]
19. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
20. Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab.
Jácome AA; Eng C
Expert Opin Biol Ther; 2019 Dec; 19(12):1247-1263. PubMed ID: 31642347
[No Abstract] [Full Text] [Related]
[Next] [New Search]